(Q40375510)

English

A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia

scientific article published on December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

13

object named as

John C Byrd

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

12

object named as

James T Dalton

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

author name string

Thomas S Lin

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Wendy Stock

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Huiping Xu

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Mitch A Phelps

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Margaret S Lucas

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sara K Guster

6

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Bruce R Briggs

7

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Carolyn Cheney

8

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Pierluigi Porcu

9

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Ian W Flinn

10

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Michael R Grever

11

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1958-1963

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Humanization and characterization of the anti-HLA-DR antibody 1D10.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

Lymphocyte programmed cell death is mediated via HLA class II DR.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

The challenge of drug-induced aseptic meningitis

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

Endothelial expression of MHC class II molecules in autoimmune disease

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

HLA-DR53 protects against thrombotic thrombocytopenic purpura/adult hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

Pharmacologic target-mediated drug disposition

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

Phase II Trial of Remitogen™ (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428190903186486

21 January 2018

Identifiers

10.3109/10428190903186486

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40375510&oldid=1896441311"